5am Ventures V sells $807,027 of Entrada Therapeutics stock By Investing.com

5AM Ventures V, L.P., a 10% owner and director of Entrada Therapeutics, Inc. (), recently disposed of common stock totaling $807,027. The transactions occurred over two days, with shares sold at prices ranging from $6.85 to $6.93. The timing is notable as TRDA stock has surged 24.5% over the past week, currently trading at $7.26—above the sale prices.

On July 30, 2026, 5AM Ventures V sold 114,756 shares of Entrada Therapeutics common stock at a weighted average price of $6.93 per share. According to a footnote, these shares were sold in multiple transactions at prices ranging from $6.75 to $6.95. The following day, July 31, 2026, an additional 1,718 shares were sold at $6.85 per share.

Following these transactions, 5AM Ventures V directly holds 2,846,592 shares of Entrada Therapeutics common stock. Separately, 5AM Opportunities I, L.P. indirectly holds 1,093,313 shares of common stock. 5AM Partners V, LLC serves as the sole general partner of 5AM Ventures V, and 5AM Opportunities I (GP), LLC is the sole general partner of 5AM Opportunities I, L.P. Dr. Kush Parmar and Andrew J. Schwab are managing members of these general partners and may be deemed to have shared voting and investment power over the shares beneficially owned. Dr. Parmar, who is also a director of Entrada Therapeutics, files separate Section 16 reports. InvestingPro analysis suggests the stock is fairly valued near current levels, with earnings results due in eight days.

In other recent news, Entrada Therapeutics Inc. has received clearance from an independent Data Monitoring Committee to proceed with a higher dose in its ELEVATE-45-201 study for Duchenne Muscular Dystrophy (DMD). The committee has recommended increasing the dose to 10 mg/kg for Cohort 2, following a review of safety and pharmacokinetic data from the initial 5 mg/kg dose used in Cohort 1. Additionally, Entrada Therapeutics is set to report topline results from Cohort 1 of its Phase 1/2 ELEVATE-44-201 clinical study of ENTR-601-44. The company plans to release these results on Thursday, with an investor webcast and conference call scheduled for 8:30 a.m. ET to discuss the findings. These developments are part of the company’s ongoing efforts to advance its clinical studies. Investors and stakeholders are likely to pay close attention to the forthcoming data and its implications for the company’s research progress.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.